Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?
Open Access
- 1 January 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (1), 5-8
- https://doi.org/10.1158/0008-5472.can-07-2038
Abstract
The RAF family members, A-Raf, B-Raf, and C-Raf (or Raf-1), are intermediate molecules in the mitogen-activated protein (MAP) kinase [Ras/Raf/MAP kinase/extracellular signal–regulated kinase (Erk) kinase (MEK)/Erk] pathway, which relays extracellular signals from the cell membrane to the nucleus via a cascade of phosphorylation events ultimately promoting cancer development. This pathway is activated by mutation in ∼7% of all human cancers. B-Raf is one of the proteins frequently mutated to an active form during tumor development. Therefore, B-Raf is an attractive cancer target but lack of clinical efficacy using agents targeting this protein has raised serious doubts about its therapeutic utility. Design of more effective B-Raf inhibitory agents, targeting other members of the signaling cascade for greater clinical efficacy or inhibiting B-Raf in combination with other targets, is being evaluated to resolve these perplexing issues. Here, we discuss recent progress, using preclinical models and clinical studies, to resolve the controversy of whether B-Raf would be a good therapeutic target for melanoma and other malignancies. [Cancer Res 2008;68(1):5–8]Keywords
This publication has 18 references indexed in Scilit:
- Targeting Mutant (V600E)B-Rafin Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma ExtravasationCancer Research, 2007
- Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling PathwayJournal of Investigative Dermatology, 2007
- Sorafenib for the Treatment of Advanced Renal Cell CarcinomaClinical Cancer Research, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma CellsJournal of Pharmacology and Experimental Therapeutics, 2006
- Targeting Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung MetastasesCancer Research, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- BRAFE600-associated senescence-like cell cycle arrest of human naeviNature, 2005
- Absence of exon 15BRAF germline mutations in familial melanomaHuman Mutation, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002